https://www.selleckchem.com/products/ym201636.html
articularly important as the therapeutic landscape for RA continues to evolve. We observed a conservative trend with TNFi as the main therapeutic choice for patients with RA and inadequate response to MTX. Preference for bDMARD-based strategies increased with the number of RA-poor prognosis factors, whereas an increase in the number of comorbidities resulted in an increased preference for ABA. Understanding clinical decision-making will be particularly important as the therapeutic landscape for RA continues to evolve. To develop a pred
Мне нравится
Комментарий
Перепост
